IP Library Patent Application 13942419
Patent Application
App. No. 13/942,419

STABLE SKIN CARE COMPOSITIONS AND METHODS FOR MANUFACTURING THEM

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/942,419
Abstract

Stable hydroquinone compositions useful for skin care have a shelf life of up to three years without discoloration.

Claims (42)

1 . A composition comprising:

hydroquinone; a preservative; a chelating agent; an emulsifier; a humectant; a pH adjuster; an antioxidant; an emollient; a reducing agent and water,

wherein the composition maintains an acceptable color for three years.

2 . The composition of claim 1 , wherein the acceptable color is a color lighter than brown.

3 . The composition of claim 1 , wherein the composition is prepared in a passivated metal tank, and wherein the discoloration of the composition is slowed compared to the discoloration of the same composition that has not been prepared in the passivated metal tank

4 . The composition of claim 1 , wherein the composition has a reduced concentration of trace metals, and wherein the reduction in the concentration of trace metals is achieved by passivating a metal tank before preparing the composition in the passivated metal tank.

5 . The composition of claim 1 , wherein the preservative comprises benzoic acid, benzyl alcohol, butylparaben, diazolidinyl urea, 2,3-Imidazolidinedione, isopropylparaben, isobutylparaben, methylparaben, propylparaben, sodium butylparaben, sorbic acid, or combinations thereof.

6 . The composition of claim 1 , wherein the chelating agent comprises citric acid, edetate disodium, ethylenediaminetetraacetic acid, etidronic acid sodium dihydroxyethylglycinate, nitrilotriacetic acid, or combinations thereof.

7 . The composition of claim 1 , wherein the emulsifier comprises cetearyl alcohol, ethoxylated fatty alcohols, PEG-1000 monocetyl ether, alkyl trimethyl ammonium bromide, polyol ester glycerol monostearate, potassium stearate, sodium lauryl sulfate, sodium cetearyl sulfate, saponins, or combinations thereof.

8 . The composition of claim 1 , wherein the humectant comprises glycerin, diglycerin, triglycerin, polyglycerin, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, ethylene glycol monoalkyl ether, diethylene glycol monoalkyl ether, glucose, maltose, sucrose, lactose, xylitose, xylitol, sorbitol, mannitol, maltitol, panthenol, pentaerythritol, hyaluronic acid, or combinations thereof.

9 . The composition of claim 1 , wherein the pH adjuster comprises citric acid, phosphoric acid, lactic acid, glycolic acid, or combinations thereof.

10 . The composition of claim 1 , wherein the antioxidant comprises ascorbyl palmitate, 2,6 ditertiarybutyl-4-methyl phenol, butylated hydroxyanisole, tocopherol, tocopheryl acetate, propyl gallate, or combinations thereof.

11 . The composition of claim 1 , wherein the emollient comprises cetyl alcohol, stearyl alcohol, liquid hydrocarbon oil, liquid natural oil, liquid fatty alcohol, liquid fatty acid, liquid fatty acid ester, liquid silicone oil, paste wax, or combinations thereof.

12 . The composition of claim 1 , wherein the reducing agent comprises ascorbic acid, propyl gallate, sodium metabisulfite, or combinations thereof.

13 . The composition of claim 1 , wherein the composition has a viscosity of from about 1,000 to about 50,000 centipoise.

14 . The composition of claim 1 , wherein the chelating agent is present in the composition in an amount ranging from about 0.05 to about 5%.

15 . A composition comprising:

hydroquinone, cetyl alcohol, stearyl alcohol, propylparaben, butylparaben, tocopherol acetate, butylated hydroxytoluene, methylparaben, edetate disodium, glycerin, sodium lauryl sulfate, saponins, lactic acid, and water,

wherein the composition is prepared in a passivated metal tank, and wherein the composition maintains an acceptable color for three years.

16 . A composition comprising:

hydroquinone;

one or more preservatives selected from the group consisting of methylparaben, propylparaben, butylparaben and combinations thereof;

edetate disodium;

one or more emulsifiers selected from the group consisting of sodium lauryl sulfate, saponins and combinations thereof;

glycerin;

lactic acid;

one or more antioxidants selected from the group consisting of tocopherol acetate, butylated hydroxytoluene, and combinations thereof;

one or more emollients selected from the group consisting of cetyl alcohol, stearyl alcohol and combinations thereof;

one or more reducing agents selected from the group consisting of ascorbic acid, sodium metabisulfite and combination thereof; and

water,

wherein the composition is prepared in a passivated metal tank, and wherein the composition maintains an acceptable color for three years.

17 . A method of making an oil-in-water emulsion comprising mixing hydroquinone; a preservative; a chelating agent; an emulsifier; a humectant; a pH adjuster; an antioxidant; an emollient; a reducing agent and water,

wherein the oil-in-water emulsion is prepared in a passivated metal tank, and wherein the oil-in-water emulsion maintains an acceptable color for three years.

18 . The method of claim 17 , wherein the preservative comprises benzoic acid, benzyl alcohol, butylparaben, diazolidinyl urea, 2,3-Imidazolidinedione, isopropylparaben, methylparaben, propylparaben, sodium butylparaben, sorbic acid, or combinations thereof.

19 . The method of claim 17 , wherein the chelating agent comprises citric acid, edetate disodium, ethylenediaminetetraacetic acid, etidronic acid sodium dihydroxyethylglycinate, nitrilotriacetic acid, or combinations thereof.

20 . The method of claim 17 , wherein the emulsifier comprises cetearyl alcohol, ethoxylated fatty alcohols, PEG-1000 monocetyl ether, alkyl trimethyl ammonium bromide, polyol ester glycerol monostearate, potassium stearate, sodium lauryl sulfate, sodium cetearyl sulfate, saponins, or combinations thereof.

21 . The method of claim 17 , wherein the humectant comprises glycerin, diglycerin, triglycerin, polyglycerin, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, ethylene glycol monoalkyl ether, diethylene glycol monoalkyl ether, glucose, maltose, sucrose, lactose, xylitose, xylitol, sorbitol, mannitol, maltitol, panthenol, pentaerythritol, hyaluronic acid, or combinations thereof.

22 . The method of claim 17 , wherein the pH adjuster comprises citric acid, phosphoric acid, lactic acid, glycolic acid, or combinations thereof.

23 . The method of claim 17 , wherein the antioxidant comprises ascorbyl palmitate, 2,6 ditertiarybutyl-4-methyl phenol, butylated hydroxyanisole, tocopherol, tocopheryl acetate, propyl gallate, or combinations thereof.

24 . The method of claim 17 , wherein the emollient comprises cetyl alcohol, stearyl alcohol, liquid hydrocarbon oil, liquid natural oil, liquid fatty alcohol, liquid fatty acid, liquid fatty acid ester, liquid silicone oil, paste wax, or combinations thereof.

25 . The method of claim 17 , wherein the reducing agent comprises ascorbic acid, propyl gallate, sodium metabisulfite, or combination thereof.

26 . A composition manufactured according to the method of claim 17 .

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OMP, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0244 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OMP, INC.
Reel/Frame 044765/0176 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OMP, INC.
Reel/Frame 044439/0790 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OMP, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0751 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2015
From: RAMIREZ, JOSE E.; MCNAMARA, AUSTIN; HATTENDORF, JUDY; GOLDNER, STEVE
To: OMP, INC.
Reel/Frame 034877/0246 →